Nivolumab infusion reaction manifesting as plantar erythema and pulmonary infiltrate in a lung cancer patient

Infusion reaction is an adverse event of therapeutic monoclonal antibodies. Nivolumab, an anti‐programmed death‐1 antibody, directly activates T cells, which could probably interact with endothelial cells. The etiology of infusion reaction induced by nivolumab may differ from that of other antibodies; however, the detailed clinical features are unknown. We report a case of lung cancer treated with nivolumab, in which the infusion reaction manifested as plantar erythema, followed by a transient local pulmonary infiltrate around the tumor. Physicians should be aware that an infusion reaction induced by anti‐programmed death‐1 antibodies could appear as local cutaneous and pulmonary adverse events.